Dysregulation of hematopoiesis in immunotherapy

Research in the lab of Michael Nemeth, PhD, centers on understanding the mechanisms by which dysregulation of blood cell development – also known as “hematopoiesis” – in the context of cancer results in an immunologic milieu that is unable to support successful immunotherapy.

Dr. Nemeth’s team is particularly interested in studying this problem in patients with blood cell cancers such as myelodysplastic syndromes (MDS) and in patients with solid tumors such as breast cancer.

Lab Research

Research focus: Myelodysplastic syndromes

Figure from a scientific research study

Our experience with immunotherapy in myeloid cancers suggests that understanding of immunologic milieu in these diseases is required to maximize the response to therapy.

MDS research

MDS clinical trials

Elizabeth Griffiths, MD, director of Roswell Park Comprehensive Cancer Center’s MDS patient services, works closely with Dr. Nemeth as she leads important clinical trials for emerging therapies and vaccine studies.

Clinical trial: NCT03358719

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

View details

Clinical trial: NCT04484532

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients with Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

View details

Research focus: Triple negative breast cancer

With funding through a Breakthrough Award from the Department of Defense (DoD), Dr. Nemeth and Roswell Park colleague Scott Abrams, PhD, aim to improve the efficacy of immune checkpoint inhibitors by eliminating the production of myeloid-derived suppressor cells (MDSCs).

TNBC researchDoD research highlights

Webinar: New approaches with immunotherapies and breast cancer
“Tempering the Hostile Tumor Microenvironment to Boost Immunotherapy Outcomes in Triple-Negative Breast Cancer”

Dr. Nemeth and Dr. Abrams talked with the Breast Cancer Alliance and Focused Ultrasound Foundation about their work in understanding the processes that limit the efficacy of immune checkpoint inhibitors.

Watch on YouTube


Get to know our principal investigator, lab members, and research collaborators.

Meet the team


Research from the Nemeth Lab has been published in numerous influential journals.

Read the research

Contact Information

Connect with the Nemeth Lab

Email: Michael.Nemeth@RoswellPark.org
Phone: 716-845-1775

Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263